Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Drug induced interstitial lung disease in oncology phase I trials.
Yonemori K, Hirakawa A, Kawachi A, Kinoshita F, Okuma H, Nishikawa T, Tamura K, Fujiwara Y, Takebe N. Yonemori K, et al. Cancer Sci. 2016 Dec;107(12):1830-1836. doi: 10.1111/cas.13087. Cancer Sci. 2016. PMID: 27685762 Free PMC article.
Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers.
Okuma HS, Yonemori K, Kojima Y, Tanioka M, Sudo K, Noguchi E, Hijioka S, Wakakuwa K, Kato K, Hirakawa A, Kuchiba A, Kubo T, Ichikawa H, Yoshida A, Yatabe Y, Nakamura K, Mano H, Yamamoto N, Fujiwara Y. Okuma HS, et al. Front Oncol. 2021 Nov 24;11:732525. doi: 10.3389/fonc.2021.732525. eCollection 2021. Front Oncol. 2021. PMID: 34900683 Free PMC article.
Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study.
Koyama T, Shimizu T, Kojima Y, Sudo K, Okuma HS, Shimoi T, Ichikawa H, Kohsaka S, Sadachi R, Hirakawa A, Yoshida A, Ando RM, Ueno T, Yanagaki M, Matsui N, Nakamura K, Yamamoto N, Yonemori K. Koyama T, et al. Among authors: okuma hs. Cancer Discov. 2023 Aug 4;13(8):1814-1825. doi: 10.1158/2159-8290.CD-23-0419. Cancer Discov. 2023. PMID: 37369013 Clinical Trial.
Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial).
Okuma HS, Watanabe K, Tsuchihashi K, Machida R, Sadachi R, Hirakawa A, Ariyama H, Kanai M, Kamikura M, Anjo K, Hiramitsu A, Sekine S, Okita N, Mano H, Nishikawa H, Nakamura K, Yonemori K. Okuma HS, et al. Clin Cancer Res. 2023 Dec 15;29(24):5079-5086. doi: 10.1158/1078-0432.CCR-23-1807. Clin Cancer Res. 2023. PMID: 37819940 Free PMC article. Clinical Trial.
38 results